Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Xvivo Perfusion AB (publ)
  6. Summary
    XVIVO   SE0004840718

XVIVO PERFUSION AB (PUBL)

(XVIVO)
  Report
Delayed Nasdaq Stockholm  -  05/20 11:29:50 am EDT
236.50 SEK   -7.80%
05/19CHU Toulouse in France starts liver and lung perfusion programs using XVIVO technologies
AQ
05/19Chu Toulouse in France Starts Liver and Lung Perfusion Programs Using XVIVO Technologies
CI
05/18XVIVO to advance their digital transformation journey in partnership with the world-leading Cleveland Clinic to increase the number of successful lung transplants
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
228(c) 238.5(c) 248(c) 256.5(c) 236.5(c) Last
16 762 10 717 15 171 21 548 22 328 Volume
+1.11% +4.61% +3.98% +3.43% -7.80% Change
More quotes
Estimated financial data (e)
Sales 2022 390 M 39,2 M 39,2 M
Net income 2022 18,3 M 1,84 M 1,84 M
Net cash position 2022 292 M 29,3 M 29,3 M
P/E ratio 2022 319x
Yield 2022 -
Sales 2023 533 M 53,5 M 53,5 M
Net income 2023 43,6 M 4,38 M 4,38 M
Net cash position 2023 316 M 31,7 M 31,7 M
P/E ratio 2023 136x
Yield 2023 -
Capitalization 6 976 M 700 M 700 M
EV / Sales 2022 17,1x
EV / Sales 2023 12,5x
Nbr of Employees 118
Free-Float 72,0%
More Financials
Company
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale... 
Read more
More about the company
Ratings of Xvivo Perfusion AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about XVIVO PERFUSION AB (PUBL)
05/19CHU Toulouse in France starts liver and lung perfusion programs using XVIVO technologie..
AQ
05/19Chu Toulouse in France Starts Liver and Lung Perfusion Programs Using XVIVO Technologie..
CI
05/18XVIVO to advance their digital transformation journey in partnership with the world-lea..
AQ
05/18Xvivo Perfusion AB Announces to Advance Their Digital Transformation Journey in Partner..
CI
05/12Reimbursement established for lung and liver transplant in the Netherlands based on res..
AQ
05/04XVIVO has executed agreements with leading US hospitals and delivered the first Kidney ..
AQ
05/04Xvivo Perfusion AB Has Executed Agreements with Leading US Hospitals and Delivered the ..
CI
04/27XVIVO submits an IDE application to US FDA for its innovative heart technology – ..
AQ
04/27Xvivo Submits an Ide Application to US FDA for Its Innovative Heart Technology - A Sign..
CI
04/27Certain Shares of Xvivo Perfusion AB are subject to a Lock-Up Agreement Ending on 27-AP..
CI
04/26Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
AQ
04/25TRANSCRIPT : Xvivo Perfusion AB, Q1 2022 Earnings Call, Apr 25, 2022
CI
04/25XVIVO presents interim report January-March 2022
AQ
04/25Xvivo Perfusion AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/21AddLife Names New President/CEO
MT
More news
News in other languages on XVIVO PERFUSION AB (PUBL)
05/19Le Chu Toulouse en France lance des programmes de perfusion du foie et des poumons en u..
05/18Xvivo Perfusion AB (publ) annonce l'avancement de son parcours de transformation numéri..
05/04Xvivo Perfusion AB (Publ) a conclu des accords avec des hôpitaux américains de premier ..
04/27Xvivo soumet une demande d'Ide à la FDA américaine pour sa technologie cardiaque innova..
04/25Xvivo Perfusion AB (publ) annonce ses résultats pour le premier trimestre clos le 31 ma..
More news
Chart XVIVO PERFUSION AB (PUBL)
Duration : Period :
Xvivo Perfusion AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XVIVO PERFUSION AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 236,50 SEK
Average target price 385,75 SEK
Spread / Average Target 63,1%
EPS Revisions
Managers and Directors
Dag Andersson Chief Executive Officer
Kristoffer Nordström Chief Financial Officer & Head-investor Relations
Gösta Per Johannesson Chairman
Andreas Wallinder Chief Medical Officer
Charlotte Walldal Director-Global Research & Development
Sector and Competitors
1st jan.Capi. (M$)
XVIVO PERFUSION AB (PUBL)-15.08%700
ABBOTT LABORATORIES-19.54%198 277
MEDTRONIC PLC-0.89%137 548
BECTON, DICKINSON AND COMPANY2.66%71 922
HOYA CORPORATION-22.41%37 902
BAXTER INTERNATIONAL INC.-14.69%36 873